1Kishi S, Yang W, Boureau B, et al.Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia[J].Blood, 2004,103(1) :67.
2Kishi S, Cheng C, French D, et al.Ancestry and pharma- cogenetics of antileukemic drug toxicity[J]. Blood, 2007, 109(10):4 151.
3Aplenc R, Glatfelter W, Han P, et al.CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia[J]. Br J Haematol, 2003,122(2) :240.
4Anderer G, Schrappe M, Brechlin AM, et al. Polymor- phisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblas- tic leukaemia[J]. Pharmacogenetics, 2000,10(8) : 715.
5Marino S, Verzegnassi F, Tamaro P, et al.Response to glucocorticoids and toxicity in childhood acute lympho- blastic leukemia: role of polymorphisms of genes in- volved in glucocorticoid response[J]. Pediatr Blood Can- cer,2009,53(6) :984.
6Swerts K, De MB, Dhooge C, et al.Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia[J]. Eur J Cancer, 2006,42 (3):295.
7Jamroziak K, Mlynarski W, Balcerczak E, et al.Function- al C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia[J]. Eur J Haematol, 2004, 72(5):314.
8Yang YL, Lin DT, Chang SK, et al.Pharmacogenomic var- iations in treatment protocols for childhood acute lympho- blastic leukemia[J]. Pediatr Blood Cancer, 2010,54 (2) : 206.
9Meissner B, StanuUa M, Ludwig WD, et al.The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leuke- mia[J]. Leukemia, 2004,18 (11) : 1 920.
10Zhou SF. Drugs behave as substrates, inhibitors and induc- ers of human cytochrome P450 3A4[J].Curr Drug Metab, 2008,9(4):310.
2Narawa T,Tsuda Y, Itoh T. Chiral recognition of amethopterin enantiomers by the reduced folate carrier in Caco- 2 cells[J ]. Drug Metab Pharmacokinet, 2007, 22(1) :33.
3Laverdiere C, Chiass on S, Costea I, et al . Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia[J]. Blood, 2002,100(10) : 3 832.
5Bosson G. Reduced folate carrier: biochemistry and molecular biology of the normal and methotrexate - resistant cell[J ] .Br J Biomed Sci, 2003, 60(2) : 117.
6Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy[J ] . Cancer Metastasis Rev,2007,26(1) : 111.
7Chango A, Emery - Fillon N, Potier de Courcy G, et al. A polymorphism(80G- > A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia[J]. Mol Genet Metab, 2000, 70(4): 310.
8Whetstine JR, Gifford AJ, Witt T, et al. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high - frequency G/ A variant at position 80 and transport properties of the His(27) and Arg(27) carriers[J]. Clin Cancer Res, 2001,7(11) :3 416.
9Shimasaki N, Mori T, Samejima H, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high - dose methotrexate - induced toxicities in children with acute lymphoblastic leukemia or lymphoma[J] . J Pediatr Hematol Oncol, 2006,28(2) : 64.
10Imanishi H, Okamura N, Yagi M,et al. Genetic poly- morphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma[J ] .J Hum Genet , 2007, 52(2) : 166.
5Swerdlow SH, Campo E, Harris NL. World Health Organization clas- sification of tumors of haematopoietic and lymphoid tissues[ M ]. Ly- on : IARC Press, 2008.
6Klimek VM.Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia.Curr Opin Hematol,2013,20(2):137-143.
7Smith SM,Le Beau MM,Huo D,et al.Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia:the University of Chicago series.Blood,2003,102(1):43-52.
8Leone G,Fianchi L,Pagano L,et al.Incidence and susceptibility to therapy-related myeloid neoplasms.Chem Biol Interact,2010,184(1-2):39-45.
9Seedhouse C,Faulkner R,Ashraf N,et al.Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia.Clin cancer Res,2004,10(8):2675-2680.
10Eichenauer DA,Thielen I,Haverkamp H,et al.Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma:a report from the German Hodgkin Study Group.Blood,2014,123(11):1658-1664.
